Home › Research › Treatments
[Advances in Anti-Dementia Therapies in Older Adults]
Schnieder M, von Arnim C.. Deutsche medizinische Wochenschrift (1946), 2026-05-29
Topic: Risk, prevention and care in population studies
Plain-language summary
Abstract The rising prevalence of dementia, driven by demographic aging, underscores the urgent need for effective therapeutic strategies. This update reviews recent advances in anti-dementia treatments, focusing on pharmacological and non-pharmacological interventions. Acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) and the NMDA receptor agonist memantine, traditionally used for Alzheimer's disease, are now recommended off-label for vascular dementia, offering modest cognitive benefits with manageable side effects. The approval of amyloid-targeting monoclonal antibodies - lecanemab and donanemab - marks a paradigm shift, as these agents demonstrate disease-modifying potential in mild cognitive impairment (MCI) and early Alzheimer's disease by reducing amyloid plaques and slowing cognitive decline. However, their use is complicated by amyloid-related imaging abnormalities (ARIA), necessitating careful patient selection and monitoring, particularly in APOE4 homozygotes. Non-pharmacological approaches, including cognitive and physical training, have gained prominence. Regular moderate exercise (150 minutes/week) improves cognitive function in MCI and dementia, while multimodal interventions (e.g., FINGER, POINTER) target risk reduction through lifestyle modifications. Digital health applications, such as "Neuronation" and "Memodio", offer promising adjuncts, though evidence remains limited. The failure of GLP-1 analogs (e.g., semaglutide) in recent trials highlights the challenges in repurposing metabolic agents for neurodegeneration. The introduction of disease-modifying therapies emphasizes the importance of early diagnosis and comprehensive geriatric assessment to balance efficacy, safety, and patient-centered outcomes. Ongoing research and real-world data will further clarify the long-term benefits and risks of these innovations, shaping future dementia care.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Schnieder, M., & von Arnim, C. (2026). [Advances in Anti-Dementia Therapies in Older Adults]. Deutsche medizinische Wochenschrift (1946). https://doi.org/10.1055/a-2676-7649
Vancouver
Schnieder M, von Arnim C. [Advances in Anti-Dementia Therapies in Older Adults]. Deutsche medizinische Wochenschrift (1946). 2026. doi:10.1055/a-2676-7649. PMID: 42214359.
BibTeX
@article{schnieder2026-42214359,
author = {Schnieder, M. and von Arnim, C.},
title = {{[Advances in Anti-Dementia Therapies in Older Adults]}},
journal = {Deutsche medizinische Wochenschrift (1946)},
year = {2026},
doi = {10.1055/a-2676-7649},
pmid = {42214359},
url = {https://doi.org/10.1055/a-2676-7649}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Regular moderate exercise (150 minutes/week) improves cognitive function in MCI and dementia, while multimodal interventions (e.g., FINGER, POINTER) target risk reduction through lifestyle modifications.
- Digital health applications, such as "Neuronation" and "Memodio", offer promising adjuncts, though evidence remains limited.
- The failure of GLP-1 analogs (e.g., semaglutide) in recent trials highlights the challenges in repurposing metabolic agents for neurodegeneration.
- The introduction of disease-modifying therapies emphasizes the importance of early diagnosis and comprehensive geriatric assessment to balance efficacy, safety, and patient-centered outcomes.
- Ongoing research and real-world data will further clarify the long-term benefits and risks of these innovations, shaping future dementia care.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 43/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 25 of the 58 points we could judge it on, which is 43 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Deutsche medizinische Wochenschrift (1946)) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42214359) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 25 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 25 of the 58 points we could judge it on is 43 out of 100. |
| Total | 43 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “advances”
5 studies in the library carry the topic tag “advances”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 5 tagged studies.